vial of semaglutide Flex-Dose 4 mL Injectable 2.5 mg/mL GLP-1 (S) - Simon's Compounding

Long-term deficiency can lead to serious heart and neurological problems

Long-acting IGF-1 activity Reduced IGFBP binding leaves more available, giving a longer half-life and about three times the potency of native IGF-1

Other TRIUMPH Trials Additional Phase 3 trials in the TRIUMPH program are ongoing: TRIUMPH-1: Retatrutide in obesity (general population), results expected 2026 TRIUMPH-2: Retatrutide in type 2 diabetes, results expected 2026 TRIUMPH-3: Retatrutide cardiovascular outcomes trial, results expected 2027 Visualize Your Retatrutide Journey See how retatrutide builds up in your system over time and compare different dosing protocols

A 2 mg target dose is 2,000 mcg

In snacking , appetite suppression is leading to a decline in snacking frequency and volume